Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.
Treating HIV very early can shrink viral reservoir 100-fold.
People living with HIV are learning how to cope with a new pandemic.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
The latest revision recognizes the importance of treatment as prevention.
Around 38,000 new HIV cases still occur each year, and more than 80% of people who could benefit from PrEP aren’t using it.
Long-acting injectables may be given once every other month, according to new findings.
The Miami program IDEA Exchange provides secure locations to store meds.
Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.
Over $12 million in grants has been awarded to the Wistar Institute to research the links between opioid receptors and immune activation.
A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Merck’s experimental HIV drug proves effective and well tolerated
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.